SXTC NASDAQ
China SXT Pharmaceuticals, Inc.
1W: -6.2%
1M: +8.6%
3M: +0.8%
YTD: -99.1%
1Y: +47.0%
3Y: -90.2%
5Y: -99.9%
$2.41
-0.55 (-18.58%)
Weekly Expected Move ±23.2%
$1
$2
$2
$3
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$35M
+60.4% ▲
5Y CAGR: +0.1%
Total Liabilities
$5M
-18.9% ▼
5Y CAGR: -23.0%
Shareholders Equity
$30M
+92.4% ▲
5Y CAGR: +13.2%
Cash & Investments
$28M
+55.7% ▲
5Y CAGR: +16.1%
Total Debt
$1M
+13.9% ▲
5Y CAGR: +91.6%
Net Debt
-$27M
-58.1% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $16M | $17M | $12M | $18M | $28M |
| Short-Term Investments | $0 | $0 | $0 | $138K | $0 |
| Cash & ST Investments | $16M | $17M | $12M | $18M | $28M |
| Net Receivables | $6M | $1M | $1M | $2M | $3M |
| Inventory | $1M | $531K | $810K | $828K | $3M |
| Other Current Assets | $385K | $231K | $7K | $30K | $145K |
| Total Current Assets | $22M | $20M | $14M | $21M | $35M |
| Property, Plant & Equip. | $2M | $1M | $565K | $355K | $239K |
| Goodwill & Intangibles | $39K | $28K | $19K | $12K | $6K |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Assets | $9M | $9M | $8M | $0 | $0 |
| Total Non-Current Assets | $11M | $10M | $9M | $367K | $245K |
| Total Assets | $34M | $30M | $23M | $22M | $35M |
| — Liabilities — | |||||
| Accounts Payable | $1M | $1M | $1M | $1M | $498K |
| Short-Term Debt | $2M | $3M | $2M | $711K | $423K |
| Deferred Revenue | $77K | $166K | $188K | $59K | $104K |
| Other Current Liabilities | $123K | $8M | $3M | $728K | $2M |
| Total Current Liabilities | $17M | $14M | $9M | $6M | $4M |
| Long-Term Debt | $0 | $118K | $117K | $96K | $644K |
| Other Non-Current Liab. | $0 | $0 | $0 | $0 | $0 |
| Total Non-Current Liabilities | $0 | $366K | $295K | $212K | $698K |
| Total Liabilities | $17M | $15M | $9M | $6M | $5M |
| — Equity — | |||||
| Common Stock | $162K | $914K | $4M | $45M | $64M |
| Retained Earnings | -$16M | -$22M | -$25M | -$28M | -$34M |
| Accumulated OCI | $956K | -$198K | -$1M | -$1M | -$198K |
| Total Stockholders Equity | $16M | $15M | $14M | $15M | $30M |
| Total Liabilities & Equity | $34M | $30M | $23M | $22M | $35M |
| — Key Metrics — | |||||
| Total Debt | $2M | $4M | $3M | $984K | $1M |
| Net Debt | -$13M | -$14M | -$9M | -$17M | -$27M |
| Total Investments | $0 | $0 | $0 | $138K | $0 |